Development and Validation of a TNF Family-Based Signature for Predicting Prognosis, Tumor Immune Characteristics, and Immunotherapy Response in Colorectal Cancer Patients

<div>Tenfold cross-validation for tuning parameter selection. (a) LASSO coefficient profiles of the nine prognostic genes (originally identified in the univariate Cox regression analyses). (b) Plots of the cross-validation error rates.</div>

Journal of Immunology Research

fig1

Figure 1

Figure 1: Development and Validation of a TNF Family-Based Signature for Predicting Prognosis, Tumor Immune Characteristics, and Immunotherapy Response in Colorectal Cancer Patients 

Figure 1 | Development and Validation of a TNF Family-Based Signature for Predicting Prognosis, Tumor Immune Characteristics, and Immunotherapy Response in Colorectal Cancer Patients 